Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 5-year average of 15.09%, near the high end of its 5-year range (-656700.00%–92.19%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
15.09%
GROSS MARGIN AVG 10Y
-19.35%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
+100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Inhibikase Therapeutics, Inc.
Market Cap
$261.43M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
15.09%
Market Cap
$261.27M
Gross Margin
81.22%
TTM Avg
75.50%
3Y Avg
37.75%
5Y Avg
35.00%
Market Cap
$262.92M
Gross Margin
85.79%
TTM Avg
85.31%
3Y Avg
84.59%
5Y Avg
70.69%
Market Cap
$259.56M
Gross Margin
41.38%
TTM Avg
41.46%
3Y Avg
41.37%
5Y Avg
45.85%
Market Cap
$259.49M
Gross Margin
79.45%
TTM Avg
80.09%
3Y Avg
80.50%
5Y Avg
80.39%
Market Cap
$259.14M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$259.12M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $261.43M | 0.00% | 0.00% | 0.00% | 15.09% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | 81.22% | 75.50% | 37.75% | 35.00% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | 85.79% | 85.31% | 84.59% | 70.69% |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | 41.38% | 41.46% | 41.37% | 45.85% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | 79.45% | 80.09% | 80.50% | 80.39% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | 0.00% | 0.00% | 25.00% | 50.00% |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | 0.00% | 0.00% | 25.00% | 16.67% |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | 93.41% | 92.41% | 88.66% | 85.93% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | -656700.00% |
| 2023-09-30 | 91.75% |
| 2023-06-30 | -36.76% |
| 2023-03-31 | 92.19% |
| 2022-12-31 | 92.07% |
| 2022-09-30 | 76.94% |
| 2022-06-30 | -45415.61% |
| 2022-03-31 | -6454.26% |
| 2021-12-31 | -174295.99% |
| 2021-09-30 | -860.41% |
| 2021-06-30 | -74.79% |
| 2021-03-31 | -72.82% |
| 2020-12-31 | -33.17% |
| 2020-09-30 | -219.98% |
| 2020-06-30 | -19.85% |
| 2020-03-31 | -4.55% |
| 2019-12-31 | -11.50% |
| 2019-09-30 | -104.91% |
| 2019-06-30 | -183.98% |
| 2019-03-31 | -163.20% |
| 2018-12-31 | 0.00% |
| 2018-03-31 | 15.32% |
| 2017-12-31 | 0.00% |
| 2017-03-31 | -3.85% |
